New York, January 26, 2026, 14:50 (EST) — Regular session
- AbbVie shares climbed roughly 0.4% in afternoon trading, following a volatile session range
- Investors are gearing up ahead of AbbVie’s Feb. 4 earnings report and its outlook for 2026
- Health-care stocks stayed resilient amid focus on the Fed and a packed earnings schedule
AbbVie Inc. shares edged up roughly 0.4% to hit $220.10 in afternoon trading on Monday, fluctuating between $217.15 and $221.48 earlier in the session.
The stock’s modest shift is notable since it hits a key pressure point for the sector: earnings, guidance, and Washington risk are all converging now.
Health-care stocks have attracted buyers following a late-2025 rally, despite analysts lowering their fourth-quarter earnings growth outlook to roughly 0.2% year over year, according to Charles Schwab. The note highlighted FactSet projections for AbbVie, expecting earnings per share of $2.65 on $16.4 billion in revenue.
Risk appetite was firmer. U.S. stocks climbed ahead of Wednesday’s Federal Reserve decision and a wave of major earnings reports. Chris Larkin of E*Trade at Morgan Stanley noted, “Wednesday’s Fed announcement will likely keep politics in the headlines.” Reuters
The health-care sector’s leading ETF ticked up roughly 0.4%. Johnson & Johnson added 0.5%, Pfizer climbed 0.6%, but Merck dipped around 0.6%.
AbbVie plans to release its full-year and fourth-quarter 2025 earnings on Wednesday, Feb. 4, ahead of the market open. The company will hold a conference call at 8 a.m. Central time, it announced.
Investors are keen for updates on AbbVie’s recent policy moves. On Jan. 12, the company announced a voluntary deal with the Trump administration. It features lower Medicaid prices, expanded direct-to-patient services via TrumpRx, and a $100 billion U.S. commitment to R&D and capital investment over the next decade. CEO Robert A. Michael said the agreement aims to “move beyond policies that harm American innovation.” AbbVie News Center
AbbVie’s main operational focus remains on immunology. The company is relying heavily on Skyrizi and Rinvoq to make up for declining Humira sales, which have dropped since the older drug lost U.S. exclusivity and faced competition from cheaper biosimilars — near-identical versions of complex biologic medicines. Humira hit peak global sales of over $21 billion in 2022, while AbbVie projects Rinvoq and Skyrizi will generate more than $31 billion in sales by 2027.
Still, a narrow stock range can work against AbbVie. Should its 2026 forecast fall short, or if investors grow wary of pricing pressures and policy compromises, that defensive buying could swiftly flip to selling.
Traders will next focus on Wednesday’s Fed statement before turning to AbbVie’s Feb. 4 earnings and guidance, with particular attention on the outlook for its immunology franchise.
